Literature DB >> 171104

A simple method for the determination of oestrogen receptor concentrations in breast tumours and other tissues.

R A Hawkins, A Hill, B Freedman.   

Abstract

A simple method for the determination of oestrogen receptor activity in breast tumours and other tissues is described. By competition between radioactive and non-radioactive oestradiol-17beta for binding to a tissue extract prepared with centrifugation at low speed, the presence or absence of receptors is decided from the unmanipulated data. The concentration of receptors (P0) and dissociation constant of binding (Kd) are calculated by Scatchard analysis. In two relatively homogeneous tissues, assay precision was of the order of 16% for receptor concentration and 21-33% for the dissociation constant of binding: in heterogeneous breast tumors, much poorer precision can be expected. Sensitivity determined empirically is approximately 0.1 fmol/mg tissue. The method has been applied to the determination of receptor concentrations in human breast cancers, benign breast tumours, non-malignant breast, gynaecomastic breast, and in various tissues of the rat. Receptor activity was detected in 70% of the human breast cancers examined, and in lower amounts, in 21% of the benign human breast tissues. Activity was also detected in rat uterus and mammary gland, and in low amounts in 82% of the rat mammary tumours analysed. Dissociation constant of binding was generally of the order of 0.5 x 10(-10) M. The advantages of the method are discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 171104     DOI: 10.1016/0009-8981(75)90202-8

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  28 in total

1.  The H-ras oncogene product p21 and prognosis in human breast cancer.

Authors:  D M Watson; R A Elton; W J Jack; J M Dixon; U Chetty; W R Miller
Journal:  Breast Cancer Res Treat       Date:  1991 Jan-Feb       Impact factor: 4.872

2.  Assessment of oestrogen receptor content of breast carcinoma by immunohistochemical techniques on fixed and frozen tissue and by biochemical ligand binding assay.

Authors:  D A Paterson; C P Reid; T J Anderson; R A Hawkins
Journal:  J Clin Pathol       Date:  1990-01       Impact factor: 3.411

Review 3.  Epidemiology and endocrinology of benign breast disease.

Authors:  D Y Wang; I S Fentiman
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

4.  Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer.

Authors:  W R Miller; D M Watson; W Jack; U Chetty; R A Elton
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Tumour steroid hormone synthesis and estrogen receptor status in breast cancer patients.

Authors:  R C Mason; D A Burns; W R Miller; R A Hawkins; A P Forrest
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

6.  Cellularity and the quantitation of estrogen receptors.

Authors:  R C Mason; R J Steele; R A Hawkins; W R Miller; A P Forrest
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

7.  Effects of drugs associated with hyperprolactinemia on plasma steroids and on steroid receptors and metabolism in human breast cancer.

Authors:  R C Mason; W R Miller; R A Hawkins; M S Brown; A P Forrest
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

8.  Oestrogen receptor concentration in primary breast cancer and axillary node metastases.

Authors:  R A Hawkins; R Black; R J Steele; J M Dixon; A P Forrest
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

9.  The differing predictive values of oestrogen receptor assays for large breast cancers.

Authors:  D J Gaskell; R A Hawkins; A L Tesdale; K Sangster; U Chetty; A P Forrest
Journal:  Postgrad Med J       Date:  1992-11       Impact factor: 2.401

10.  Cyclic AMP binding proteins and prognosis in breast cancer.

Authors:  W R Miller; R A Elton; J M Dixon; U Chetty; D M Watson
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.